Learn More
AIMS AND HYPOTHESIS Giant intracranial aneurysms have a poor prognosis mainly due to their high risk of rupture. Because their incidence is low, clinical trial evidence for adequate treatment is lacking. The Giant Intracranial Aneurysm Registry is designed to document current treatment strategies in giant aneurysm care and to monitor the course of the(More)
Large and giant anterior communicating artery (ACoA) aneurysms usually show partial thrombosis and incorporate both the A(1) and A(2) segments and crucial perforating vessels. Therefore, direct clip placement or endovascular strategies often fail, leaving cerebral bypass surgery as a relevant therapeutic option. The authors present 3 cases in which a giant(More)
Intracranial aneurysms (IA) are usually quantified according to their largest diameter. However, volumetry has recently been increasingly conducted as well, especially in giant intracranial aneurysms (GIAs). Since so far the true value of GIA volumetry is unknown, we designed a trial to examine correlations between GIA diameter and volume with special focus(More)
To compare the safety and effectiveness of minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants vs conservative management (CM) in patients with chronic sacroiliac joint (SIJ) pain. 103 adults with chronic SIJ pain at nine sites in four European countries were randomly assigned to and underwent either minimally invasive SIJF(More)
Giant intracranial aneurysms (GIA) are often not eligible for direct clip occlusion. Surgical alternatives include partial clip occlusion or the placement of a cerebrovascular bypass or the combination of both. These alternative indirect strategies are expected to lead to a decrease in GIA volume over time rather than instantaneously. To examine whether(More)
BACKGROUND Intrathecal interleukin (IL)-6 is considered to be a proinflammatory biomarker for cerebral inflammatory response. This is of clinical importance for the prediction of vasospasm after subarachnoid haemorrhage (SAH). We evaluated a bedside technique for the quantitative measurement of IL-6 in the cerebrospinal fluid (CSF). MATERIAL/METHODS 32(More)
The Giant Intracranial Aneurysm Registry is a multicenter observational trial exclusively focusing on giant intracranial aneurysms (GIA). As no data exist on the interobserver variability in the radiological description of GIA, there is some uncertainty concerning the reliability of the GIA characteristics included in the registry. We have therefore(More)
BACKGROUND Infections are the leading cause of death in the acute phase following spinal cord injury and qualify as independent risk factor for poor neurological outcome ("disease modifying factor"). The enhanced susceptibility for infections is not stringently explained by the increased risk of aspiration in tetraplegic patients, neurogenic bladder(More)
BACKGROUND The major side-effects of bevacizumab in glioma treatment are venous thromboembolic events (VTE). We retrospectively evaluated factors potentially predictive of thromboembolic events. PATIENTS AND METHODS Bevacizumab, alone or in combination with chemotherapy was used as salvage therapy for recurrence in malignant glioma every two weeks. None(More)
Cerebral tissue oxygenation (PbrO2) is most frequently monitored using a Licox CC1.SB system (LX, Integra Neuroscience, France) but recently a new probe—the Neurovent-PTO (NV)—was introduced by a different manufacturer (Raumedic, Germany). There are no prospective data on how these probes compare in clinical routine. We therefore compared both probes in(More)